GSK
GSK·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GSK
Gsk Plc
A UK-based developer of pharmaceuticals for respiratory and rdiovascular diseases, viruses, and vaccines
Pharmaceutical
12/06/1999
10/29/2001
New York Stock Exchange
68,629
12-31
Depository Receipts (Ordinary Shares)
980 Great West Road, Brentford, Middlesex TW8 9GS England
Development and production of medicines and vaccines
GSK Plc, established in the United Kingdom on December 6, 1999, is a world-leading research-based pharmaceutical and healthcare company, formed by the merger of Glaxo Wellcome plc and SmithKline Beecham plc. The company is committed to developing new products that are significantly improved over existing treatment options, providing assistance to patients and governments, insurance companies or other third parties.
Earnings Call
Q3/2025
Estimate EPS1.26
Actual EPS0.670806
Estimate Revenue10.93B
Actual Revenue11.49B
GSK's Q3 2025 Earnings Call: Contradictions Unveiled in Blenrep's 2031 Outlook, Nucala COPD Sales, Shingrix Market Dynamics, and HIV Revenue Impact
Oct 29,2025 12:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GSK has released its 2025 Q2 earnings. EPS was reported at 1.24, versus the expected 1.11, beating expectations. The chart below visualizes how GSK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GSK has released its 2025 Q3 earnings report, with revenue of 11.49B, reflecting a YoY change of 7.03%, and net profit of 2.88B, showing a YoY change of 3209.29%. The Sankey diagram below clearly presents GSK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
